Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vanda Pharmaceuticals reports mixed Q4 results amid legal challenges and opportunities

Vanda Pharmaceuticals faces financial challenges with declining revenues and HETLIOZ sales, offset by increased cash reserves and positive clinical trial outcomes.
Legal battles and uncertainties add complexity to the company's financial outlook, requiring strategic planning and risk management.
Despite hurdles, opportunities for growth exist through new drug applications, market expansion, and potential partnerships to drive future success.

Vanda Pharmaceuticals reports resilient Q1 performance amidst generic challenges

Vanda Pharmaceuticals delivered a strong performance in Q1 2023, navigating challenges from generic competition while focusing on growth opportunities.
The company's financial results and strategic initiatives position it well for future expansion and innovation in the pharmaceutical industry.
Despite uncertainties surrounding litigation and generic competition, Vanda remains resilient and committed to driving long-term value for stakeholders.

Vanda Pharmaceuticals navigates revenue decline, eyes regulatory approvals for growth

Vanda Pharmaceuticals faced revenue challenges due to generic competition impacting HETLIOZ sales, leading to a revenue decline.
Despite legal uncertainties and revenue setbacks, the company showcased strength in pipeline progress and operational cost management.
Management's confidence in regulatory outcomes and strategic flexibility positions Vanda for potential growth opportunities.

Vanda Pharmaceuticals reports revenue decline but maintains positive net income

Vanda Pharmaceuticals faces revenue challenges with declining total revenues and net product sales in 2023.
Despite this, the company maintains positive net income and focuses on upcoming FDA decisions for growth.
Strong leadership, operational efficiency, and a diversified product portfolio are key strengths for Vanda.
Exploring growth opportunities through FDA decisions, market expansion, and strategic initiatives is crucial for future success.

Vanda Pharmaceuticals reports revenue decline, pursues new treatments amid challenges

Vanda Pharmaceuticals faced revenue declines and net losses in Q4 2023, driven by challenges in product sales and market conditions.
Despite these setbacks, the company is strategically expanding its product portfolio and pursuing new treatments to drive future growth.
Navigating legal battles, generic competition, and market uncertainties will be key focus areas for Vanda in the coming year.

Vanda Pharmaceuticals navigates revenue challenges, eyes growth through strategic initiatives

Vanda Pharmaceuticals faced revenue challenges due to generic competition but remains focused on driving growth through commercial strategies.
The company's psychiatry portfolio expansion and ongoing clinical programs position it well for future market opportunities.
Addressing shareholder activism and evaluating takeover proposals while maintaining operational focus are key challenges ahead.
Engaging with the FDA for product approvals and planning strategic marketing initiatives offer avenues for revenue growth.

Vanda Pharmaceuticals reports revenue growth and strategic expansion plans

Vanda Pharmaceuticals is navigating a mixed financial performance with revenue growth but a net loss in Q2 2024. The company's focus on expanding its commercial organization and advancing clinical development indicates a strategic approach to drive future growth amidst challenges from generic competition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TrueBlue

Townsquare Media

Vimeo

VNDA, TSQ, SPPJY, VMEO and TBI have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2024.

New Strong Buy Stocks for November 14th

WASHINGTON , Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2024: The Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024. A corporate presentation is scheduled for 9:45 a.m.

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023 Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash ranges Fanapt® launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023 Fanapt® long acting injectable program expected to be initiated in Q4 2024 Milsaperidone NDA for schizophrenia and bipolar I disorder expected to be submitted in early 2025; initiation of major depressive disorder program expected in Q4 2024 PONVORY® commercial launch for multiple sclerosis initiated in Q3 2024 PONVORY® IND applications for psoriasis and ulcerative colitis expected to be submitted in Q4 2024 Tradipitant NDA for motion sickness expected to be submitted in Q4 2024 WASHINGTON , Nov. 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2024. "We are very pleased with the lead indicators of the initial market response to our commercial launch of Fanapt in bipolar I disorder, a testament to the strong clinical evidence and the strength of our commercial strategy, and we look forward to continuous growth in the coming quarters.

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024, during which management will discuss the third quarter 2024 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises

Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders WASHINGTON , Oct. 14, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it received a second unsolicited, non-binding proposal from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash.

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

UK-based Cycle Pharmaceuticals on Monday reaffirmed its offer to buy Vanda Pharmaceuticals in a deal that values the US drugmaker at $488 million, despite a regulatory setback for its stomach condition drug in September.

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (“Cycle”), a dynamic leader in developing rare disease therapies, today reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) for an all-cash consideration of $8.00 per Vanda share. Cycle is making its renewed proposal public for the benefit of Vanda shareholders in light of the Vanda Board's continued refusal to engage following the receipt of mu.

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

Vanda Pharmaceuticals Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - VNDA

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

VNDA ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Vanda Pharmaceuticals Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

Levi & Korsinsky Reminds Vanda Pharmaceuticals Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – VNDA

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

Shareholders That Lost Money on Vanda Pharmaceuticals Inc. (VNDA) Should Contact Levi & Korsinsky About Securities Fraud Investigation - VNDA

NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

Vanda Pharmaceuticals Inc. Being Investigated on Behalf of Vanda Pharmaceuticals Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

ATTENTION VNDA SHAREHOLDERS: Investors who lost money on Vanda Pharmaceuticals Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Vanda Pharmaceuticals Inc. (VNDA)

NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

Vanda Pharmaceuticals Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VNDA

The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis

NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

Vanda Pharmaceuticals Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VNDA

The biotech had discouraging news to report about one of its pipeline drugs. The FDA declined to approve its application.

Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today

The company has criticized the FDA for failing to hold advisory committee meetings as well as going against the FDCA.

Vanda Pharmaceuticals decries FDA's rejection of stomach paralysis drug as unjust

Thursday, the FDA declined to approve Vanda Pharmaceuticals Inc.'s VNDA New Drug Application (NDA) of tradipitant for symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies

The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals' drug to treat stomach paralysis symptoms, the company said on Thursday.

News for Vanda Pharmaceuticals Stock (VNDA)